Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with conf...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentile, Ivan, Scotto, Riccardo, Schiano Moriello, Nicola, Pinchera, Biagio, Villari, Riccardo, Trucillo, Emilia, Ametrano, Luigi, Fusco, Ludovica, Castaldo, Giuseppe, Buonomo, Antonio Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607194/
https://www.ncbi.nlm.nih.gov/pubmed/36298596
http://dx.doi.org/10.3390/vaccines10101731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607194/
https://www.ncbi.nlm.nih.gov/pubmed/36298596
http://dx.doi.org/10.3390/vaccines10101731

Ejemplares similares